Role of global assays in thrombosis and thrombophilia

Pediatric Thrombotic Disorders

Volumn , Issue , 2014, Pages 142-157

  Chitlur, Meera ^a   Simpson, Mindy L ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84954285562     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139028882.012     Document Type: Chapter

References (72)

1. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002 Jul 1;100(1):148-52.
2. Hartert H. [Not Available]. Klin Wochenschr. 1948 Oct 1;26(37-38):577-83.
3. Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS, et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma. 2009 Aug;67(2):266-75;discussion 75-6.
4. Chitlur M, Lusher J. Standardization of thromboelastography: values and challenges. Semin Thromb Hemost. 2010 Oct;36(7):707-ll.
5. Chitlur M, Sorensen B, Rivard GE, Young G, Ingerslev J, Othman M, et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia. 2011 May;17(3):532-7.
6. Herbstreit F, Winter EM, Peters J, Hartmann M. Monitoring of haemostasis in liver transplantation: comparison of laboratory based and point of care tests. Anaesthesia. 2010 Jan;65(1):44-9.
7. De Pietri L, Montalti R, Begliomini B, Scaglioni G, Marconi G, Reggiani A, et al. Thromboelastographic changes in liver and pancreatic cancer surgery: hypercoagulability, hypocoagulability or normocoagulability? Eur J Anaesthesiol. 2010 Jul;27(7):608-16.
8. Hvitfeldt Poulsen L, Christiansen K, Sorensen B, Ingerslev J. Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients. Scand J Clin Lab Invest. 2006;66(4):329-36.
9. Kupesiz A, Rajpurkar M, Warrier I, Hollon W, Tosun O, Lusher J, et al. Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography. Blood Coagul Fibrinolysis. 2010 Jun;21(4):320-4.
10. Kupesiz OA, Chitlur MB, Hollon W, Tosun O, Thomas R, Warrier I, et al. Fibrinolytic parameters in children with noncatheter thrombosis: a pilot study. Blood Coagul Fibrinolysis. 2010 Jun;21(4):313-19.
11. Kashuk JL, Moore EE. The emerging role of rapid thromboelastography in trauma care. J Trauma. 2009 Aug;67 (2):417-18.
12. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. NEngl J Med. 1994 Dec;331(24):1601-6.
13. Watters JM, Sambasivan CN, Zink K, Kremenevskiy I, Englehart MS, Underwood SJ, et al. Splenectomy leads to a persistent hypercoagulable state after trauma. Am J Surg. May 2010;199(5):646-51.
14. Copeland H, Nolan PE, Covington D, Gustafson M, Smith R, Copeland JG. A method for anticoagulation of children on mechanical circulatory support. Artif Organs. 2011 Nov;35(11):1018-23.
15. Andreasen JB, Hvas AM, Christiansen K, Ravn HB. Can RoTEM(R) analysis be applied for haemostatic monitoring in paediatric congenital heart surgery? Cardiol Young. 2011 Dec;21 (6):684-91.
16. Moganasundram S, Hunt BJ, Sykes K, Holton F, Parmar K, Durward A, et al. The relationship among thromboelastography, hemostatic variables, and bleeding after cardiopulmonary bypass surgery in children. Anesth Analg. 2010 Apr;110(4):995-1002.
17. Holcomb JB, Minei KM, Scerbo ML, Radwan ZA, Wade CE, Kozar RA, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg. Sep;256 (3):476-86.
18. Differding JA, Underwood SJ, Van PY, Khaki RA, Spoerke NJ, Schreiber MA. Trauma induces a hypercoagulable state that is resistant to hypothermia as measured by thromboelastogram. Am J Surg. May;201(5):587-91.
19. Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res. 2005;116(4):345-56.
20. Antovic A. The overall hemostasis potential: a laboratory tool for the investigation of global hemostasis. Semin Thromb Hemost. 2010 Oct;36(7):772-9.
21. He S, Bremme K, Blomback M. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. Thromb Res. 1999 Oct;96(2):145-56.
22. He S, Antovic A, Blomback M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb Res. 2001 Sep;103(5):355-61.
23. Bombardier C, Villalobos-Menuey E, Ruegg K, Hathaway WE, Manco-Johnson MJ, Goldenberg NA. Monitoring hypercoagulability and hypofibrinolysis following acute venous thromboembolism in children: application of the CloFAL assay in a prospective inception cohort study. Thromb Res. 2012 Sep;130(3):343-9.
24. Goldenberg NA, Hathaway WE, Jacobson L, McFarland K, Manco-Johnson MJ. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A. Haemophilia. 2006 Nov;12(6):605-14.
25. Goldenberg NA, Bombardier C, Hathaway WE, McFarland K, Jacobson L, Manco-Johnson MJ. Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B. Haemophilia. 2008 Jan;14(1):68-77.
26. Antovic A, Blomback M, Sten-Linder M, Petrini P, Holmstrom M, He S. Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. Blood Coagul Fibrinolysis. 2005 Nov;16(8):585-96.
27. Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen HN, Jorneskog G, et al. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis. 2003 Sep;14(6):551-6.
28. Antovic JP, Rafik Hamad R, Antovic A, Blomback M, Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation? Thromb Haemost. 2002 Oct;88(4):644-7.
29. Anzej S, Bozic M, Antovic A, Peternel P, Gaspersic N, Rot U, et al. Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia. Thromb Res. 2007;120(1):39-46.
30. Rooth E, Wallen H, Antovic A, von Arbin M, Kaponides G, Wahlgren N, et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis. 2007 Jun;18(4):365-70.
31. Antovic A, Blomback M, Bremme K, Van Rooijen M, He S. Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance. J Thromb Haemost. 2003 Dec;1(12):2531-5.
32. Andresen MS, Abildgaard U. Coagulation inhibitor potential: a study of assay variables. Thromb Res. 2005;115(6):519-26.
33. Andresen MS, Abildgaard U, Liestol S, Sandset PM, Mowinckel MC, Odegaard OR, et al. The ability of three global plasma assays to recognize thrombophilia. Thromb Res. 2004;113(6):411-17.
34. Andresen MS, Iversen N, Abildgaard U. Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin. Thromb Res. 2002 Dec; 108(5-6):323-8.
35. Antovic A, Blomback M, Bremme K, He S. The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, and treatment in pregnant women with previous thromboembolism. Blood Coagul Fibrinolysis. 2002 Apr;13(3):181-6.
36. Smith AA, Jacobson LJ, Miller BI, Hathaway WE, Manco-Johnson MJ. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res. 2003;112(5-6): 329-37.
37. Rijken DC, Hoegee-de Nobel E, Jie AF, Atsma DE, Schalij MJ, Nieuwenhuizen W. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost. 2008 Jan;6(1):151-7.
38. Kowalski E, Kopec M, Niewiarowski. An evaluation of the euglobulin method for the determination of fibrinolysis. J Clin Pathol. 1959 May;12(3):215-18.
39. Swiatkiewicz A, Jurkowski P, Kotschy M, Ciecierski M, Jawien, A. Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis. Med Sci Monit. 2002 Apr;8(4): CR263-8.
40. Doig RG, O’Malley CJ, Dauer R, McGrath KM. An evaluation of 200 consecutive patients with spontaneous or recurrent thrombosis for primary hypercoagulable states. Am J Clin Pathol. 1994 Dec;102 (6):797-801.
41. Harbourne T, O’Brien D, Nicolaides AN. Fibrinolytic activity in patients with idiopathic and secondary deep venous thrombosis. Thromb Res. 1991 Dec 1;64(5):543-50.
42. Sloan IG, Firkin BG. Impaired fibrinolysis in patients with thrombotic or haemostatic defects. Thromb Res. 1989 Sep;55(5):559-67.
43. Rijken DC, Kock EL, Guimaraes AH, Talens S, Murad SD, Janssen HL, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost. 2012 Oct;10(10):2116-22.
44. van der Pas R, de Bruin C, Leebeek FW, de Maat MP, Rijken DC, Pereira AM, et al. The hypercoagulable state in Cushing’s disease is associated with increased levels ofprocoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab. 2012 Apr;97(4):1303-10.
45. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res. 2011 Feb;127(Suppl 3):S21-5.
46. Macfarlane RG, Biggs R. A thrombin generation test: the application in haemophilia and thrombocytopenia. JClin Pathol. 1953 Feb;6(1):3-8.
47. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53.
48. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006 Nov;96(5):553-61.
49. Baglin T. Using the laboratory to predict recurrent venous thrombosis. Int J Lab Hematol. 2011 Aug;33(4):333-42.
50. Duchemin J, Pan-Petesch B, Arnaud B, Blouch MT, Abgrall JF. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost. 2008 Apr;99(4):767-73.
51. Vanschoonbeek K, Feijge MA, Van Kampen RJ, Kenis H, Hemker HC, Giesen PL, et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost. 2004 Mar;2(3):476-84.
52. Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyak K, Ten Cate H, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2008 Jan;6(1):125-31.
53. Haidl H, Cimenti C, Leschnik B, Zach D, Muntean W. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). Thromb Haemost. 2006 May;95(5):772-5.
54. Fritsch P, Kleber M, Rosenkranz A, Fritsch M, Muntean W, Mangge H, et al. Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels. Atherosclerosis. 2010 Oct;212(2):650-5.
55. Segers O, van Oerle R, Ten Cate H, Rosing J, Castoldi E. Thrombin generation as an intermediate phenotype for venous thrombosis. Thromb Haemost. 2010 Jan;103 (1):114-22.
56. Rosenkranz A, Hiden M, Leschnik B, Weiss EC, Schlembach D, Lang U, et al. Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost. 2008 Feb;99(2):331-7.
57. Tchaikovski SN, van Vliet HA, Thomassen MC, Bertina RM, Rosendaal FR, Sandset PM, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost. 2007 Dec;98(6):1350-6.
58. Bernhard H, Deutschmann A, Leschnik B, Schweintzger S, Novak M, Hauer A, et al. Thrombin generation in pediatric patients with Crohn’s disease. Inflamm Bowel Dis. 2011 Nov;17(11):2333-9.
59. Couturaud F, Duchemin J, Leroyer C, Delahousse B, Abgrall JF, Mottier D. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study. Thromb Haemost. 2008 Jan;99(1):223-8.
60. Lavigne-Lissalde G, Sanchez C, Castelli C, Alonso S, Mazoyer E, Bal Dit Sollier C, et al. Prothrombin G20210A carriers: the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. J Thromb Haemost. 2010 May;8(5):942-9.
61. Castoldi E, Simioni P, Tormene D, Thomassen MC, Spiezia L, Gavasso S, et al. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost. 2007 May;5(5):971-9.
62. Alhenc-Gelas M, Canonico M, Picard V. Influence of natural SERPINC1 mutations on ex vivo thrombin generation. J Thromb Haemost. 2010 Apr;8(4):845-8.
63. Castoldi E, Maurissen LF, Tormene D, Spiezia L, Gavasso S, Radu C, et al. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica. 2010 Sep;95 (9):1563-71.
64. Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography +/-thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost. 2006 Nov;96(5):562-7.
65. Ten Cate-Hoek AJ, Dielis AW, Spronk HM, van Oerle R, Hamulyak K, Prins MH, et al. Thrombin generation in patients after acute deep-vein thrombosis. Thromb Haemost. 2008 Aug;100(2):240-5.
66. van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. BrJ Haematol. 2007 Sep; 138 (6):769-74.
67. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2008 Aug;6 (8):1327-33.
68. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate ofunprovoked recurrent venous thrombosis is associated with high thrombingenerating potential in a prospective cohort study. J Thromb Haemost. 2008 Oct;6(10):1720-5.
69. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006 Jul 26;296(4):397-402.
70. Simpson ML, Goldenberg NA, Jacobson LJ, Bombardier CG, Hathaway WE, Manco-Johnson MJ. Simultaneous thrombin and plasmin generation capacities in normal and abnormal states ofcoagulation and fibrinolysis in children and adults. Thromb Res. 2011 Apr;127(4):317-23.
71. van Geffen M, Loof A, Lap P, Boezeman J, Laros-van Gorkom BA, Brons P, et al. A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis. Hematology. 2011 Nov;16(6):327-36.
72. van Geffen M, van Heerde WL. Global haemostasis assays, from bench to bedside. Thromb Res. 2012 Jun;129(6):681-7.